Facioscapulohumeral Muscular Dystrophy Type 2INSIGHT FSHD2NCT06079567
An 18-month Prospective Natural History Study to Gain Insight Into FSHD2 Pathophysiology and Disease Progression
A study testing Validation of new COMs for FSHD2 patients in people with Facioscapulohumeral Muscular Dystrophy Type 2, run by Centre Hospitalier Universitaire de Nice at 9 sites in 5 countries.
Trial summary
Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common inherited myopathies in adults. It is associated with genetic and epigenetic deregulation of the D4Z4 locus on the sub-telomeric region of chromosome 4q35, resulting in abnormal expression of DUX4p. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Facioscapulohumeral Muscular Dystrophy Type 2
- What is being tested?
- Validation of new COMs for FSHD2 patients
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 9 sitesin 5 countries
- Study dates
- 3 Oct 2023to Mar 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Genetically confirmed FSHD2: pathogenic mutation in SMCHD1 gene and at least one D4Z4 4qA allele;
- Age 18-75 years
- Symptomatic limb weakness
- Clinical severity score of 2 to 5 (RICCI score; range 0-5), inclusive, at screening:
- Group ambulant patient with a RICCI score of 2 to 4
- Group non-ambulant patient with a RICCI score of 5
Show all 28Show fewer
- Patient giving written consent after written and oral information
- Patient affiliated to a social security system
- If taking over the counter supplements, willing to remain consistent with supplement regimen throughout the course of the study
- Non inclusion criteria:
- Patients with comorbidity not related to the disease that can modify the natural evolution of the disease or would interfere with safe testing in the opinion of the Investigator
- Regular use of available muscle anabolic/catabolic agents such as corticosteroids, oral testosterone or derivatives, or oral beta agonists
- Contraindication to muscle MRI as per clinic standard practice
- Patients who has been to a tropical or subtropical country during the last 3 months
- Patients who has practiced physical exercise within 10 hours before blood test
- Patients declaring not to be fasting for at least 10 hours
- Patients following a particular diet for medical reasons and after prescription by a doctor or dietitian
- Patients who regularly consumes large quantities of alcohol
- Patients having consumed an illicit recreational drug during the last 3 months
- Patients having been vaccinated during the last 3 months
- Patients having received a blood transfusion or immunoglobulins during the last 3 months
- Patients declaring to be seropositive for HIV, HBV or HCV
- Patients having had an infectious episode during the 3 weeks preceding the visit
- Use of an experimental drug in an FSHD clinical trial within the past 30 days
- Participation in others clinical trials
- Pregnant women, breastfeeding women, women of childbearing age without contraception Pregnancy
- Patient with legal protection measures (future protection mandate, family empowerment, guardianship, curators) under Article L. 1122-2 of the French Public Health Code
- Patient refusing to participate in the study or expressing opposition to participation
Who cannot join
None listed.
Trial locations and contacts
9 sites in 5 countries. Contact the study team or a site near you to ask about taking part.
9 sites in 5 countries
France3 sites, 3 recruiting
- Recruiting
APHM
Marseille, Bouches Du Rhone, 13005
Shahram ATTARIAN, 0491386579 ext. +33, sattarian@ap-hm.fr
Shahram ATTARIAN
- Recruiting
Nice University Hospital
Nice, Alpes M, 06000
Sabrina SACCONI, 0492035757 ext. +33, sacconi.s@chu-nice.fr
Sabrina SACCONI
- Recruiting
Myology Institute
Paris, 75000
Marion MASINGUE, 0142163776 ext. +33, marion.masingue@ap-hp.fr
Marion MASINGUE
Italy3 sites, 3 recruiting
- Recruiting
Nemo Center
Milan, Lombardy, 20162
Valeria SANSONE, 0291433756 ext. +39, valeria.sansone@centrocliniconemo.it
Valeria SANSONE
- Not yet recruiting
Pisa University
Pisa, Tuscany, 56126
Giulia RICCI, 0502212111 ext. +39, giulia.ricci@unipi.it
Giulia RICCI
- Recruiting
Gemelli University Hospital
Rome, Lazio, 00168
Marco ELEFANTI
Marco ELEFANTI
Belgium1 site, 1 recruiting
- Recruiting
Leuven University
Leuven, 3000
Kristl CLAEYS, 32-16-344280, Kristl.Claeys@uzleuven.be
Kristl CLAEYS
Netherlands1 site, 1 recruiting
- Recruiting
Radboud University Medical Centre Nijmegen
Nijmegen
Nicol VOERMANS, Nicol.Voermans@radboudumc.nl
Nicol VOERMANS
Spain1 site, 1 recruiting
- Recruiting
Donostia University Hospital
Donostia / San Sebastian, Guipuscoa, 20014
Adolfo Jose Lopez de Munain Arregui, ADOLFOJOSE.LOPEZDEMUNAINARREGUI@osakidetza.eus
Adolfo Jose Lopez de Munain Arregui
About this study
Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common inherited myopathies in adults. It is associated with genetic and epigenetic deregulation of the D4Z4 locus on the sub-telomeric region of chromosome 4q35, resulting in abnormal expression of DUX4p. Type 1 FSHD (FSHD1) is the most common form of the disease and accounts for 95% of cases, while Type 2 FSHD (FSHD2) accounts for only 5% of all FSHD cases. FSHD1 and FSHD2 are closely related in terms of genetic and epigenetic foundations, pathophysiology and clinical manifestations. Although initially described as distinct entities based on their genetics, recent information suggests that both forms of myopathy may represent the opposite ends of a spectrum of molecular diseases in which alteration of the genetic and epigenetic factors that govern DUX4 suppression in skeletal muscle have a different impact in both forms of the disease. FSHD1 and FSHD2 are both associated with re-expression of DUX4 leading to muscle atrophy, but the genetics underlying this re-expression are different, depending on whether it is type 1 or type 2. For FSHD1, it is associated with a critical contraction of the D4Z4 region and the 4qA permissive allele, leading to the expression of DUX4. In contrast, FSHD2 is caused by the inheritance of two independent genetic variations. A heterozygous mutation, mainly located on the SMCHD1 (Structural Maintenance of Chromosome flexible Hinge Domain containing 1) gene, results in a loss of function of chromatin D4Z4 repressor. This mutation, combined with the 4qA allele bearing the DU4 polyadenylation site, makes this allele permissive for the expression of the DUX4 topical gene.
Therefore, because the two forms of FSHD are genetically distinct and very few patients have FSHD2, our knowledge of the impact of chromatin D4Z4 repressors, such as SMCHD1, or the progression and severity of the disease remains very limited. It is important to note that a lack of reliable biomarkers specific to the severity and progression of the disease may prevent the development of therapies to treat patients with FSHD2. This study will allow us to better understand the natural progression of FSHD2 over time, to assess the responsiveness of clinical outcome measures (COMs) and to identify and validate inflammatory serum biomarkers predicting the severity and progression of the disease.
- Being tested
- Validation of new COMs for FSHD2 patients
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Validation of new COMs for FSHD2 patientsDiagnostic test
Monitoring of commonly used and new COMs in FSHD2 patients
| Study group | Role | What they receive |
|---|---|---|
| New COMs for FSHD2 patients | Experimental | Not described Receives: Diagnostic Test: Validation of new COMs for FSHD2 patients |
What is being measured
The primary outcome is the main question the study is designed to answer.
Minimal clinical importance of the Motor Function Measure-32 (MFM-32) from Baseline (V1) to 18 months (V3)
Within MFM-32, 32 terms will be evaluated to describe patient's motor functions and grouped into 3 sub-scores at baseline and 18 months:
D1: standing position and transfer D2: axial and proximal motor function D3: distal motor function The MFM-32 ratings rely on the use of a 4-point Likert scale based on the subject's maximal abilities without assistance (0: cannot initiate the task or maintain the starting position; 1: performs the task partially; 2: performs the task incompletely or imperfectly;3: performs the task fully and normally.)
Measured: At baseline and 18 months
Secondary outcomes (30)
Change of the Italian Severity Score (FCS) from Baseline (V1) to 18 months (V3)
The Italian Severity Score (FCS) ranks weakness in the face, shoulders, arms, distal, and proximal lower extremities on a 15-points scale
Measured: At baseline and 18 months
Change of the Clinical Severity Score (CSS) from Baseline (V1) to 18 months (V3)
The Clinical Severity score (CSS) ranks weakness in the face, shoulders, arms, distal, and proximal lower extremities on a 10-points scale
Measured: At baseline and 18 months
Change of the Manual Muscle Testing (MMT) from Baseline (V1) to 18 months (V3)
The Manual Muscle Testing is a modified Medical Research Council 13-point and is used with standardized positions for each grade and each muscle following the recommendations of the FSH-DY Group. Shoulder abduction and flexion, elbow flexion and extension, wrist flexion and extension, fingers flexion and extension, hip flexion and abd/adduction, knee flexion and extension, ankle plantarflexion and dorsiflexion strength will be measured bilaterally
Measured: At baseline and 18 months
Change of the Hand-Held dynamometry (HHD) from Baseline (V1) to 18 months (V3)
Hand-Held dynamometry (HHD) assess the isometric muscle strength in both the upper and lower limbs bilaterally (global shoulder abduction and flexion, elbow flexion and extension, hip abduction, knee extension, ankle dorsiflexion isometric strength). The required equipment is a calibrated hand-held dynamometer (MicroFet). The patient has to push against the hand-held dynamometer 3 times as hard as he can for 3-5 seconds. The maximal value will be kept for further analysis.
Measured: At baseline and 18 months
Change of the Pinch and Grip test from Baseline (V1) to 18 months (V3)
The purpose of those tests is to measure the maximum isometric strength of the hand and forearm muscles when doing a grasping or a pinching action. The equipment required for the grip and the pinch tests is a calibrate dynamometer. The subject should be strongly encouraged to give a maximum effort. We record three trials for each hand, alternating hands with at least 30 seconds recovery between each effort. We keep the best result.
Measured: At baseline and 18 months
Change of the 9-Hole Peg test (9-HPT) from Baseline (V1) to 18 months (V3)
The 9-Hole Peg Test is used to measure finger dexterity. The patient is seated at a table with a small, shallow container holding 9 pegs and a wood or plastic block containing nine empty holes. When a stopwatch is started, the patient picks up the 9 pegs one at a time as quickly as possible, puts them in the 9 holes, and, once they are in the holes, removes them again as quickly as possible one at a time, replacing them into the shallow container. The total time to put the pegs and to remove them (one lap) will be recorded, 3 times alternating hands. The best trial will be registered for both hands.
Measured: At baseline and 18 months
Change of the repeated 9-Hole Peg test (r9-HPT) from Baseline (V1) to 18 months (V3)
The repeated 9-Hole Peg test (r9-HPT) est a fatigability test. The same procedure like 9-HPT is repeated 5 times (5 laps) with the same hand. The total time to complete the r9-HPT is recorded and the ratio "last lap/first lap" is calculated. The patient will choose the tested hand.
Measured: At baseline and 18 months
Change of the classic Timed Up and Go test (classic TUG) from Baseline (V1) to 18 months (V3)
Balance and mobility in patients able to walk at most 30 meters will be assessed using the classic Timed Up and Go test (TUG). The classic TUG measures, in seconds, the time taken by a patient to stand up from a standard armchair (approximate seat height of 46 cm, arm height 65 cm), walk 3 meters, turn, walk back to the chair, and sit down. The best performance will be recorded.
Measured: At baseline and 18 months
Change of the optimized Timed Up and Go test (optimized TUG) from Baseline (V1) to 18 months (V3)
The optimized TUG test measures, in seconds, the time taken by patient to sit up from a lying down position (1st time interval); stand up from the mat (approximate height of 46 cm, walk 3 meters, turn, walk back to the mat, sit down (2nd time interval); and lie down to return to starting position (3rd time interval).
Measured: At baseline and 18 months
Change of the 6-Minute Walk Test (6MWT) from Baseline (V1) to 18 months (V3)
The 6MWT is a measure of functional exercise capacity that requires both strength and physical endurance. It assesses how far an individual can walk in 6 minutes and has been used widely in studies of neuromuscular disease
Measured: At baseline and 18 months
Change of the Sit Up Test (SiUT) from Baseline (V1) to 18 months (V3)
The SiUT measures, in seconds, the time taken by a patient to sit up from a lying down position and to return to the initial position.
Measured: At baseline and 18 months
Change of the repeated Sit Up Test (r-SiUT) from Baseline (V1) to 18 months (V3)
The r-SiUT measures, in seconds, the time taken by a patient to sit up from a lying down position and to return to the initial position (1 lap). This task is repeated 5 times (5 laps). The total time to complete the trial is recorded and the ratio last lap/first lap is calculated.
Measured: At baseline and 18 months
Change of the Stand Up Test (SaUT) from Baseline (V1) to 18 months (V3)
The SaUT measures, in seconds, the time taken by a patient to stand up from a standard armchair (approximate seat height of 46 cm, arm height 65 cm) and to return to the initial position.
Measured: At baseline and 18 months
Change of the repeated Stand Up Test (r-SaUT) from Baseline (V1) to 18 months (V3)
The r-SaUT measures, in seconds, the time taken by a patient to stand up from a standard armchair (approximate seat height of 46 cm, arm height 65 cm) and to return to the initial position. This task is repeated 5 times (5 laps). The total time to complete the trial is recorded and the ratio last lap/first lap is calculated.
Measured: At baseline and 18 months
Change of the Bend Over Test (BOT) from Baseline (V1) to 18 months (V3)
The BOT measures, in seconds, the time taken by the patient, to bend forward, knee in extension, to touch a support placed in front of the middle of the tibia and to return to the initial position
Measured: At baseline and 18 months
Change of the repeated Bend Over Test (r-BOT) from Baseline (V1) to 18 months (V3)
The r-BOT measures, in seconds, the time taken by the patient, to perform 5 times consecutively the following task: to bend forward, knee in extension, to touch a support placed in front of the middle of the tibia and to return to the initial position.
Measured: At baseline and 18 months
Change of the Neck Flexion Fatigability Test (NFFT) from Baseline (V1) to 18 months (V3)
The NFFT measures, in seconds, the total time that the patient can hold the following position: in a lying position, arm relaxed on each sides of the body, the patient has to raise his head from the table flexing his neck at 45°.
Measured: At baseline and 18 months
Change of the respiratory function (sitting and bedside spirometry) from Baseline (V1) to 18 months (V3)
Sitting and bedside spirometry allow to obtain forced vital capacity and forced respiratory volume in 1 second, two standardized outcomes commonly used to evaluate respiratory function in clinical follow up and clinical trials.
Measured: At baseline and 18 months
Change of the muscle composition from Baseline (V1) to 18 months (V3)
Based on T1-Dixon images, muscles will be evaluated on all available sections, and a comprehensive score describing the degree of involvement will be given between 0 (unaffected muscle) to 4 (muscle completely replaced by fatty fibrous tissue or atrophic).
A T1-MRI score will be calculated as the sum of the scores of involvement of the individual muscles in each patient.
Based on T2 Short T1 Inversion Recovery (STIR), muscles will be evaluated on all available sections, and a comprehensive score describing the degree of involvement was given between 0 (absence of STIR hyperintensity) and 1 (presence of area of STIR hyperintensity).
A STIR-Magnetic Resonance Imaging (MRI) score will be calculated as the sum of the scores of involvement of the individual muscles in each patient.
Measured: At baseline and 18 months
Change of the score for physical function and the impact of physical limitations on daily life (PROMIS57) from Baseline (V1) to 18 months (V3)
The PROMIS57 is an instrument developed by the NIH PROMIS initiative. The PROMIS®-57 scales include eight items from seven primary domains: depression, anxiety, physical function, pain interference (and pain intensity), fatigue, sleep disturbance, and satisfaction with social roles. A 5-point scale is used for each instrument, except for the 0-10 pain intensity item.
Raw scores for each of the seven short forms (domains) in PROMIS-57 are calculated, and scores are converted to T-scores for each of the seven short forms (domains) in PROMIS-57 based on the PROMIS guidelines (http:// www.healthmeasures.net).
The T-score conversion establishes 50 as a general population mean for all PROMIS domains, and any 10-point deviation corresponds to one standard deviation (SD) difference, for easy-to-understand and consistent scoring across measures.
Measured: At baseline and 18 months
Change of the score for the Patient Global Impression of Change (PGIC) from Baseline (V1) to 18 months (V3)
The PGIC items consist of 4 questions pertaining to overall disease-related symptoms, activities of daily living, as well as mobility and respiratory issues. The items range from -3 (a great deal worse) to 0 (no change) to 3 (a great deal better)
Measured: At baseline and 18 months
Change of the score for the Upper Extremity Functional Index (UEFI) from Baseline (V1) to 18 months (V3)
The Upper Extremity Functional Index (UEFI) is a validated patient reported measure for adults with upper extremity dysfunction. This index measures upper extremity dysfunction. 20 questions are combined into a total score, the score is transformed into a normalized score with 80 representing normal, and lower scores representing increasing disability.
Measured: At baseline and 18 months
Change of the score for the Facial Disability Index (FDI) from Baseline (V1) to 18 months (V3)
The Facial Disability Index (FDI) is a short 5 items questionnaire which assesses the physical impact of facial weakness. The five questions are summed into total score which transformed onto a percentage scale, with 100 representing normal, and lower scores representing increasing disability.
Measured: At baseline and 18 months
Change of the score for the Sydney Swallow Questionnaire (SSQ) from Baseline (V1) to 18 months (V3)
The Sydney Swallow Questionnaire (SSQ) is a 17 question, self-report inventory, which was developed to measure symptomatic severity of oral-pharyngeal dysphagia as reported by the affected patient. The questionnaire uses a 100mm long visual analogue scale (VAS) for all but one question.
Measured: At baseline and 18 months
Change of the score for the Swallowing Quality of Life questionnaire (SWAL-QOL) from Baseline (V1) to 18 months (V3)
The original SWAL-QOL scale has 44 items exploring patient's quality of life and grouped into 10 lifestyle scales:
burden of eating difficulty; eating duration; eating desire; food selection; communication; fear; mental health; social impact; fatigue; and sleep. There is also a symptom-frequency scale in which each item is scored from 1 to 5 (1 for poorest, 5 for best quality of life). For each scale, a separate score out of 100% is calculated, with each item having the same importance. There is no global score of QOL.
Measured: At baseline and 18 months
Change of the score for the Multidimensional Dyspnea Profile (MDP) from Baseline (V1) to 18 months (V3)
The Multidimensional Dyspnea Profile (MDP) is a questionnaire which assesses overall breathing discomfort, sensory qualities, and emotional responses in laboratory and clinical settings. The MDP assesses dyspnea during a specific time or a particular activity (focus period) and is designed to examine individual items that are theoretically aligned with separate mechanisms.
Measured: At baseline and 18 months
Change of the FSHD-Rasch-built overall disability scale (FSHD-RODS) from Baseline (V1) to 18 months (V3)
The FSHD-RODS is a patient-reported disease-specific interval measure suitable for detecting activity and participation restrictions in patients with FSHD. The FSHD-RODS consists of 32 items that range in difficulty level (e.g., ability to fill in a form, ability to run). Each item is graded on an ordinal scale, with 0 representing "unable to perform", 1 representing "able to perform, but with difficulty", and 2 representing "easily performed without difficulty". A total score will be calculated based on the sum of the item scores and will range from 0-64, with a lower score representing a higher disability
Measured: At baseline and 18 months
Change of the fatigue severity scale (FSS) from Baseline (V1) to 18 months (V3)
The FSS is a unidimensional scale which focuses on the physical aspects of fatigue. It is a self-reported questionnaire developed to measure the impact of disabling fatigue on daily functioning. It covers several areas including physical, social, and cognitive effects. The FSS is a patient-reported outcome composed of 9-items with scores ranging from 1 = "strongly disagree" to 7 = "strongly agree".
Measured: At baseline and 18 months
Change of the fall and exercise questionnaire from Baseline (V1) to 18 months (V3)
A fall and exercise questionnaire will assess average monthly falls and near falls, and average weekly amount of exercise. A standard questionnaire will ask about the effect of FSHD on work/occupation.
Measured: At baseline and 18 months
Change of the cytokines levels in serum from Baseline (V1) to 12 months (V2) and 18 months (V3)
Serum cytokines level analysis will be done using v-plex® immunoassay with the commercially available Proinflammatory Panel 1 and Cytokine Panel 1 (Meso Scale Discovery MSD). Serum cytokines level will be compared between baseline the 12-months and the 18-months follow-up.
Measured: At baseline, 12 and 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Oct 2023
- Study start3 Oct 2023
- Primary completionMar 2028 (estimated)
- Study completionMar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Facioscapulohumeral Muscular Dystrophy Type 2Studies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire de NiceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de Nice
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06079567
- Sponsor's protocol ID
- 22-PP-15
- Acronym
- INSIGHT FSHD2
- Status last verified
- Sep 2026
- First submitted
- 6 Oct 2023
- Last updated
- 3 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An 18-month Prospective Natural History Study to Gain Insight Into FSHD2 Pathophysiology and Disease Progression
- ClinicalTrials.gov ID
- NCT06079567
- Acronym / sponsor ID
- INSIGHT FSHD2 / 22-PP-15
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire de NiceUniversity, hospital or other
- Study start
- 3 Oct 2023 (actual)
- Primary completion
- Mar 2028 (estimated)
- Study completion
- Mar 2028 (estimated)
- First posted
- 12 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common inherited myopathies in adults. It is associated with genetic and epigenetic deregulation of the D4Z4 locus on the sub-telomeric region of chromosome 4q35, resulting in abnormal expression of DUX4p. Type 1 FSHD (FSHD1) is the most common form of the disease and accounts for 95% of cases, while Type 2 FSHD (FSHD2) accounts for only 5% of all FSHD cases. FSHD1 and FSHD2 are closely related in terms of genetic and epigenetic foundations, pathophysiology and clinical manifestations. Although initially described as distinct entities based on their genetics, recent information suggests that both forms of myopathy may represent the opposite ends of a spectrum of molecular diseases in which alteration of the genetic and epigenetic factors that govern DUX4 suppression in skeletal muscle have a different impact in both forms of the disease. FSHD1 and FSHD2 are both associated with re-expression of DUX4 leading to muscle atrophy, but the genetics underlying this re-expression are different, depending on whether it is type 1 or type 2. For FSHD1, it is associated with a critical contraction of the D4Z4 region and the 4qA permissive allele, leading to the expression of DUX4. In contrast, FSHD2 is caused by the inheritance of two independent genetic variations. A heterozygous mutation, mainly located on the SMCHD1 (Structural Maintenance of Chromosome flexible Hinge Domain containing 1) gene, results in a loss of function of chromatin D4Z4 repressor. This mutation, combined with the 4qA allele bearing the DU4 polyadenylation site, makes this allele permissive for the expression of the DUX4 topical gene.
Therefore, because the two forms of FSHD are genetically distinct and very few patients have FSHD2, our knowledge of the impact of chromatin D4Z4 repressors, such as SMCHD1, or the progression and severity of the disease remains very limited. It is important to note that a lack of reliable biomarkers specific to the severity and progression of the disease may prevent the development of therapies to treat patients with FSHD2. This study will allow us to better understand the natural progression of FSHD2 over time, to assess the responsiveness of clinical outcome measures (COMs) and to identify and validate inflammatory serum biomarkers predicting the severity and progression of the disease.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| New COMs for FSHD2 patients | Experimental | Diagnostic Test: Validation of new COMs for FSHD2 patients |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (28 listed)
- Genetically confirmed FSHD2: pathogenic mutation in SMCHD1 gene and at least one D4Z4 4qA allele;
- Age 18-75 years
- Symptomatic limb weakness
- Clinical severity score of 2 to 5 (RICCI score; range 0-5), inclusive, at screening:
- Patient giving written consent after written and oral information
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Validation of new COMs for FSHD2 patientsMonitoring of commonly used and new COMs in FSHD2 patients | Diagnostic test | New COMs for FSHD2 patients |
Primary outcome
Minimal clinical importance of the Motor Function Measure-32 (MFM-32) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Within MFM-32, 32 terms will be evaluated to describe patient's motor functions and grouped into 3 sub-scores at baseline and 18 months: D1: standing position and transfer D2: axial and proximal motor function D3: distal motor function The MFM-32 ratings rely on the use of a 4-point Likert scale based on the subject's maximal abilities without assistance (0: cannot initiate the task or maintain the starting position; 1: performs the task partially; 2: performs the task incompletely or imperfectly;3: performs the task fully and normally.)
30 secondary outcomes
Change of the Italian Severity Score (FCS) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the Clinical Severity Score (CSS) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the Manual Muscle Testing (MMT) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the Hand-Held dynamometry (HHD) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the Pinch and Grip test from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the 9-Hole Peg test (9-HPT) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the repeated 9-Hole Peg test (r9-HPT) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the classic Timed Up and Go test (classic TUG) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the optimized Timed Up and Go test (optimized TUG) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the 6-Minute Walk Test (6MWT) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the Sit Up Test (SiUT) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the repeated Sit Up Test (r-SiUT) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the Stand Up Test (SaUT) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the repeated Stand Up Test (r-SaUT) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the Bend Over Test (BOT) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the repeated Bend Over Test (r-BOT) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the Neck Flexion Fatigability Test (NFFT) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the respiratory function (sitting and bedside spirometry) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the muscle composition from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the score for physical function and the impact of physical limitations on daily life (PROMIS57) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the score for the Patient Global Impression of Change (PGIC) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the score for the Upper Extremity Functional Index (UEFI) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the score for the Facial Disability Index (FDI) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the score for the Sydney Swallow Questionnaire (SSQ) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the score for the Swallowing Quality of Life questionnaire (SWAL-QOL) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the score for the Multidimensional Dyspnea Profile (MDP) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the FSHD-Rasch-built overall disability scale (FSHD-RODS) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the fatigue severity scale (FSS) from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the fall and exercise questionnaire from Baseline (V1) to 18 months (V3)
Time frame: At baseline and 18 months
Change of the cytokines levels in serum from Baseline (V1) to 12 months (V2) and 18 months (V3)
Time frame: At baseline, 12 and 18 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Facioscapulohumeral Muscular Dystrophy Type 2
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
RecruitingObservational study
The United Kingdom Facioscapulohumeral Muscular Dystrophy Patient Registry
Facioscapulohumeral Muscular Dystrophy
RecruitingPhase 3
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
Facioscapulohumeral Muscular Dystrophy, FSHD
Active, not recruitingPhase 2
Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
FSHD, FSHD1
Recruiting
Personalized Training for People With Rare Neuromuscular Disorders
Neuromuscular Diseases (NMD), Charcot Marie Tooth Disease (CMT)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
9 sites in 5 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Validation of new COMs for FSHD2 patients in people with Facioscapulohumeral Muscular Dystrophy Type 2, run by Centre Hospitalier Universitaire de Nice at 9 sites in 5 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 28 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in France, Italy, Belgium, Netherlands, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sabrina SACCONI (0492035757 ext. +33, sacconi.s@chu-nice.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Minimal clinical importance of the Motor Function Measure-32 (MFM-32) from Baseline (V1) to 18 months (V3) (time frame: At baseline and 18 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.